HC Wainwright Lowers Bicara Therapeutics (NASDAQ:BCAX) Price Target to $44.00

Bicara Therapeutics (NASDAQ:BCAX - Free Report) had its price objective reduced by HC Wainwright from $45.00 to $44.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics' Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.73) EPS.

BCAX has been the topic of several other reports. Wedbush reaffirmed an "outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Stifel Nicolaus set a $48.00 price target on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $36.50.

Bicara Therapeutics Trading Up 6.1 %

BCAX traded up $0.62 during trading on Monday, hitting $10.77. 361,501 shares of the stock traded hands, compared to its average volume of 471,006. Bicara Therapeutics has a 12-month low of $8.91 and a 12-month high of $28.09. The firm has a 50-day moving average of $12.76 and a 200 day moving average of $16.82.

Remove Ads

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, research analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Red Tree Management LLC bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth $55,230,000. Adage Capital Partners GP L.L.C. increased its holdings in Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after buying an additional 1,375,265 shares in the last quarter. Braidwell LP raised its position in Bicara Therapeutics by 20.7% in the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company's stock worth $34,851,000 after buying an additional 343,059 shares during the last quarter. Deep Track Capital LP lifted its stake in Bicara Therapeutics by 151.0% during the 4th quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after acquiring an additional 1,203,148 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Bicara Therapeutics by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,547,180 shares of the company's stock valued at $26,953,000 after acquiring an additional 8,246 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.